Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cefotaxime
Drug ID BADD_D00390
Description Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).
Indications and Usage Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery.
Marketing Status approved
ATC Code J01DD01
DrugBank ID DB00493
KEGG ID D07647
MeSH ID D002439
PubChem ID 5742673
TTD Drug ID D0D1HA
NDC Product Code 0143-9933; 0143-9931; 0143-9935; 0143-9930
UNII N2GI8B1GK7
Synonyms Cefotaxime | Cephotaxim | Cefotaxim | Biosint | Cefotaxime Sodium | Sodium, Cefotaxime | Cefradil | Taporin | Fotexina | HR-756 | HR 756 | HR756 | Kendrick | Ru-24756 | Ru 24756 | Ru24756 | Benaxima | Claforan | Primafen | Klaforan
Chemical Information
Molecular Formula C16H17N5O7S2
CAS Registry Number 63527-52-6
SMILES CC(=O)OCC1=C(N2C(C(C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tubulointerstitial nephritis20.05.02.002--Not Available
Acute generalised exanthematous pustulosis23.03.10.002; 12.03.01.005; 11.07.01.018; 10.01.01.0340.000122%Not Available
Cardiopulmonary failure22.02.06.004; 02.05.01.0040.000049%Not Available
Haemorrhage24.07.01.002--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Induration08.01.03.020--Not Available
Ill-defined disorder08.01.03.049--Not Available
Renal impairment20.01.03.010--Not Available
Liver injury12.01.17.012; 09.01.07.0220.000049%Not Available
Traumatic liver injury12.01.17.027; 09.01.08.010--Not Available
Hypertransaminasaemia09.01.02.0050.000049%Not Available
Acute kidney injury20.01.03.0160.000122%
Drug reaction with eosinophilia and systemic symptoms12.03.01.064; 23.03.05.005; 10.01.01.0210.000389%Not Available
Candida infection11.03.03.021--
Drug effective for unapproved indication12.09.02.001; 08.06.01.0370.000049%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.000049%Not Available
Haemophagocytic lymphohistiocytosis01.05.01.026; 16.32.03.038; 10.02.01.0770.000049%Not Available
Vulvovaginal inflammation21.14.02.014--Not Available
The 4th Page    First    Pre   4    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene